Gan & Lee Pharmaceuticals. (SHA: 603087)
China
· Delayed Price · Currency is CNY 48.42
-1.26 (-2.54%)
Nov 13, 2024, 3:00 PM CST
Gan & Lee Pharmaceuticals. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 2,936 | 2,596 | 1,710 | 3,612 | 3,362 | 2,895 | Upgrade
|
| Other Revenue | 11.6 | 11.6 | 2.4 | 0.11 | - | - | Upgrade
|
| Revenue | 2,947 | 2,608 | 1,712 | 3,612 | 3,362 | 2,895 | Upgrade
|
| Revenue Growth (YoY) | 23.78% | 52.31% | -52.60% | 7.44% | 16.12% | 21.26% | Upgrade
|
| Cost of Revenue | 796.76 | 724.7 | 443.93 | 399.9 | 309.82 | 237.98 | Upgrade
|
| Gross Profit | 2,151 | 1,883 | 1,268 | 3,212 | 3,052 | 2,657 | Upgrade
|
| Selling, General & Admin | 1,319 | 1,163 | 1,334 | 1,302 | 1,201 | 1,075 | Upgrade
|
| Research & Development | 534.52 | 501.02 | 562.47 | 474.59 | 419.99 | 235.56 | Upgrade
|
| Other Operating Expenses | 27.8 | 23.61 | 20.37 | 26.21 | 20.98 | 16.26 | Upgrade
|
| Operating Expenses | 1,901 | 1,703 | 1,944 | 1,822 | 1,637 | 1,328 | Upgrade
|
| Operating Income | 249.64 | 180.04 | -675.68 | 1,390 | 1,415 | 1,329 | Upgrade
|
| Interest Expense | -0.55 | -0.55 | -0.78 | -0.96 | - | - | Upgrade
|
| Interest & Investment Income | 126.99 | 141.01 | 186.63 | 321.99 | 67.38 | 46.71 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.4 | 2.4 | -2.39 | -0.71 | 0.26 | -4.68 | Upgrade
|
| Other Non Operating Income (Expenses) | 5.39 | -0.8 | -1.6 | -3.34 | -3.83 | -3.4 | Upgrade
|
| EBT Excluding Unusual Items | 383.87 | 322.09 | -493.82 | 1,707 | 1,479 | 1,368 | Upgrade
|
| Gain (Loss) on Sale of Investments | 167.56 | -17.92 | -80.66 | -54.45 | -42.77 | 22.39 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.12 | -0.49 | -5.18 | -1.7 | -6.52 | -1.68 | Upgrade
|
| Asset Writedown | -9.18 | -12.55 | -40.92 | - | - | - | Upgrade
|
| Other Unusual Items | 16.35 | 15.01 | 38.1 | 44.96 | 16.12 | 9 | Upgrade
|
| Pretax Income | 558.72 | 306.14 | -582.47 | 1,696 | 1,445 | 1,397 | Upgrade
|
| Income Tax Expense | -22.3 | -34.09 | -142.96 | 243.26 | 214.76 | 230.19 | Upgrade
|
| Earnings From Continuing Operations | 581.02 | 340.23 | -439.52 | 1,453 | 1,231 | 1,167 | Upgrade
|
| Minority Interest in Earnings | -0.16 | -0.16 | 0 | 0 | 0 | 0 | Upgrade
|
| Net Income | 580.86 | 340.07 | -439.52 | 1,453 | 1,231 | 1,167 | Upgrade
|
| Net Income to Common | 580.86 | 340.07 | -439.52 | 1,453 | 1,231 | 1,167 | Upgrade
|
| Net Income Growth | 141.25% | - | - | 18.04% | 5.43% | 24.98% | Upgrade
|
| Shares Outstanding (Basic) | 589 | 567 | 563 | 561 | 533 | 505 | Upgrade
|
| Shares Outstanding (Diluted) | 589 | 567 | 563 | 561 | 533 | 505 | Upgrade
|
| Shares Change (YoY) | 3.48% | 0.59% | 0.46% | 5.28% | 5.43% | 0.09% | Upgrade
|
| EPS (Basic) | 0.99 | 0.60 | -0.78 | 2.59 | 2.31 | 2.31 | Upgrade
|
| EPS (Diluted) | 0.99 | 0.60 | -0.78 | 2.59 | 2.31 | 2.31 | Upgrade
|
| EPS Growth | 133.14% | - | - | 12.12% | 0% | 24.86% | Upgrade
|
| Free Cash Flow | 150.74 | -443.61 | -686.76 | 386.09 | 659.2 | 750.97 | Upgrade
|
| Free Cash Flow Per Share | 0.26 | -0.78 | -1.22 | 0.69 | 1.24 | 1.49 | Upgrade
|
| Dividend Per Share | 0.200 | 0.200 | - | 0.300 | 0.400 | 0.357 | Upgrade
|
| Dividend Growth | - | - | - | -25.00% | 12.01% | - | Upgrade
|
| Gross Margin | 72.97% | 72.21% | 74.07% | 88.93% | 90.78% | 91.78% | Upgrade
|
| Operating Margin | 8.47% | 6.90% | -39.46% | 38.49% | 42.08% | 45.91% | Upgrade
|
| Profit Margin | 19.71% | 13.04% | -25.67% | 40.22% | 36.61% | 40.32% | Upgrade
|
| Free Cash Flow Margin | 5.11% | -17.01% | -40.11% | 10.69% | 19.61% | 25.94% | Upgrade
|
| EBITDA | 478.21 | 394.57 | -479.87 | 1,571 | 1,574 | 1,445 | Upgrade
|
| EBITDA Margin | 16.23% | 15.13% | -28.03% | 43.49% | 46.83% | 49.91% | Upgrade
|
| D&A For EBITDA | 228.57 | 214.53 | 195.81 | 180.64 | 159.6 | 115.83 | Upgrade
|
| EBIT | 249.64 | 180.04 | -675.68 | 1,390 | 1,415 | 1,329 | Upgrade
|
| EBIT Margin | 8.47% | 6.90% | -39.46% | 38.49% | 42.08% | 45.91% | Upgrade
|
| Effective Tax Rate | - | - | - | 14.34% | 14.86% | 16.47% | Upgrade
|
| Revenue as Reported | 2,947 | 2,608 | 1,712 | 3,612 | 3,362 | 2,895 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.